NCT05505812View on ClinicalTrials.gov

Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 8, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

March 31, 2027

Conditions
Breast Cancer
Interventions
BIOLOGICAL

HS-IT101

Adoptive transfer of 1x10\^9-6x10\^10 autologous TIL to patients i.v. in 30-60 minutes.

Trial Locations (1)

Unknown

The Affiliated Hospital of Qingdao University, Qingdao

All Listed Sponsors
collaborator

Qingdao Sino-Cell Biomedicine Co., Ltd.

INDUSTRY

lead

The Affiliated Hospital of Qingdao University

OTHER

NCT05505812 - Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Breast Cancer | Biotech Hunter | Biotech Hunter